Eli Lilly & Co. and Amylin Pharmaceuticals Inc. could feel more competitive pressure in the diabetes market as their drug Byetta comes under scrutiny after new patient deaths were reported Tuesday.
Eli Lilly and Amylin Pharmaceuticals Inc. on Tuesday reported four new deaths in patients taking Byetta, even as the companies tried to shore up the safety profile of their popular diabetes medication.
An analysis of recent diabetes studies debunks the notion that aggressive blood sugar control of critically ill hospital patients with diabetes can help save lives, U.S. researchers said on Tuesday.